SM-EGN confers a persistently higher recurrence risk after curative ESD, consistent with the phenomenon of field cancerization. No significant difference in survival was observed in the limited second recurrence cohort, likely due to intensive monitoring and timely intervention. That hints to us that SM-EGN patients require lifelong, risk-adapted surveillance.
Wang et al. (Fri,) studied this question.